Study looks at factor VIII products for hemophilia A

01/17/2013 |

The odds of inhibitory antibody development were the same for children with hemophilia A who took plasma-derived factor VIII products and those in the recombinant group, a Dutch study found. Researchers reported in the New England Journal of Medicine that inhibitor development risk was not linked with the von Willebrand factor content of these products or with switching between plasma-derived and recombinant.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT